EmitX Pharmaceuticals was founded by members of the McMaster Radiochemistry Group. The McMaster Radiochemistry Group has produced world leading research in the radiopharmaceutical space as well as prostate cancer research. With close connections to many industry partners as well as access to McMaster University's nuclear facilities, we have been able to produce cutting edge research and research novel diagnostic and therapeutic agents for various types of cancer. We have built upon an exceptional foundation at McMaster: a lab environment with a proven translational pedigree established by Dr. John Valliant (whose work led to Fusion Pharmaceuticals' success, acquired by AstraZeneca for $2.4 billion), experienced personnel, and cutting-edge resources.
EmitX seeks to creatively move the current paradigm of radioligand therapy towards new and innovative solutions of patient care and treatment. By leveraging the properties of unique radioisotopes, we believe more effective and safer solutions are possible. Our strong commitment to researching how to enable these unconventional radioisotopes for therapy will lead the way towards better outcomes and change what radioligand therapy looks like forever.
